Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 7/20 | 0.49 |
| ▸ | NR1H3 | Q13133 | 7/20 | 0.49 |
| ▸ | RXRA | P19793 | 5/20 | 0.49 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | HSD17B13 | Q7Z5P4 | 6/20 | 0.33 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.33 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.32 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.30 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.30 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1030912 | 0.87 | NR1H2 (0.51) | NR1H2NR1H3RXRAP2RX7NR1I2 | |
| SCHEMBL1030550 | 0.86 | RXRA (0.49) | NR1H2NR1H3RXRAP2RX7PDE3B | |
| SCHEMBL1033338 | 0.86 | NR1H2 (0.37) | NR1H2NR1H3RXRAP2RX7HSD17B13 | |
| SCHEMBL1034179 | 0.84 | NR1H2 (0.54) | NR1H2NR1H3RXRANR1I2NR3C1 | |
| SCHEMBL1030533 | 0.83 | RXRA (0.49) | NR1H2NR1H3RXRAP2RX7MAPK14 | |
| SCHEMBL1034214 | 0.81 | RXRA (0.34) | NR1H2NR1H3RXRAP2RX7MAPK14 | |
| SCHEMBL1031492 | 0.81 | RXRA (0.46) | NR1H2NR1H3RXRAP2RX7MAPK14 | |
| SCHEMBL1033899 | 0.81 | RXRA (0.45) | NR1H2NR1H3RXRAP2RX7MAPK14 | |
| SCHEMBL1034044 | 0.81 | RXRA (0.46) | NR1H2NR1H3RXRAP2RX7MAPK14 | |
| SCHEMBL1034200 | 0.81 | RXRA (0.57) | NR1H2NR1H3RXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1572660-B1 | ISOQUINOLINONE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | X CEPTOR THERAPEUTICS INC (US) | 2011-01-26 | — | — | EP | claimed |
| US-20080132521-A1 | Isoquinolinone Derivatives and Their Use As Therapeutic Agents | EXELIXIS, INC. (US) | 2008-06-05 | — | — | US | claimed |
| US-7265131-B2 | Isoquinolinone derivatives and their use as therapeutic agents | EXELIXIS, INC. (US) | 2007-09-04 | — | — | US | claimed |
| EP-1572660-A1 | ISOQUINOLINONE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | X-Ceptor Therapeutics, Inc. (US) | 2005-09-14 | — | — | EP | claimed |
| US-20040204447-A1 | Isoquinolinone derivatives and their use as therapeutic agents | X-CEPTOR THERAPEUTICS INC. | 2004-10-14 | — | — | US | claimed |
| WO-2004058717-A1 | ISOQUINOLINONE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | X-CEPTOR THERAPEUTICS, INC. (US) | 2004-07-15 | — | — | WO | claimed |
| EP-1572660-B1 | ISOQUINOLINONE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | X CEPTOR THERAPEUTICS INC (US) | 2011-01-26 | — | — | EP | disclosed |
| US-20080132521-A1 | Isoquinolinone Derivatives and Their Use As Therapeutic Agents | EXELIXIS, INC. (US) | 2008-06-05 | — | — | US | disclosed |
| US-7265131-B2 | Isoquinolinone derivatives and their use as therapeutic agents | EXELIXIS, INC. (US) | 2007-09-04 | — | — | US | disclosed |
| EP-1572660-A1 | ISOQUINOLINONE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | X-Ceptor Therapeutics, Inc. (US) | 2005-09-14 | — | — | EP | disclosed |
| US-20040204447-A1 | Isoquinolinone derivatives and their use as therapeutic agents | X-CEPTOR THERAPEUTICS INC. | 2004-10-14 | — | — | US | disclosed |
| WO-2004058717-A1 | ISOQUINOLINONE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | X-CEPTOR THERAPEUTICS, INC. (US) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132521-A1 | Isoquinolinone Derivatives and Their Use As Therapeutic Agents | NR1H2, NR1H3, NR1I2 | NR1H2 1/4885NR1H3 2/4885RXRA 25/4885 |
| US-20040204447-A1 | Isoquinolinone derivatives and their use as therapeutic agents | NR1H2, NR1I2, NR1H3 | NR1H2 1/4885NR1H3 3/4885RXRA 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.